Document:

EX-10.7

 Exhibit 10.7 

INTELLECTUAL PROPERTY SECURITY AGREEMENT 

This Intellectual Property Security Agreement is entered into as October 13, 2017, by and among OXFORD FINANCE LLC, a Delaware limited
liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of
the Loan Agreement (as such term is defined below, each a “Lender” and collectively, the “Lenders”), and and Lombard Medical Technologies Inc., a Delaware corporation with an office located at 15420 Laguna Canyon Road,
Suite 260, Irvine CA 92618 (“Lombard Medical”) and ALTURA MEDICAL, INC., a Delaware corporation with offices located at 923 Hamilton Ave., Menlo Park, CA 94025 (“Altura” and together with Lombard Medical,
individually and collectively, jointly and severally, “Borrower”). 
 RECITALS 

A. Lenders agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “Loans”) in
the amounts and manner set forth in that certain Loan and Security Agreement by and among Lenders and Grantor dated as of April 24, 2015 (as the same may be amended, amended and restated, modified or supplemented from time to time, the
“Loan Agreement”; capitalized terms used herein are used as defined in the Loan Agreement). In accordance with the terms of the Loan Agreement, Grantor is granting to Collateral Agent, for the ratable benefit of the
Lenders, a security interest in certain Copyrights, Trademarks, Patents and Mask Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement. 

B. Grantor has already granted to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right,
title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (other than the Intellectual Property Collateral (as defined herein below)). 

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral
security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows: 

AGREEMENT 
 To secure its
obligations under the Loan Agreement, effective as of date hereof, Grantor hereby grants and pledges to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under
its intellectual property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following: 

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and
derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached
hereto (collectively, the “Copyrights”); 
 (b) Any and all trade secrets, and any and all intellectual property rights in
computer software and computer software products now or hereafter existing, created, acquired or held; 

  

 (c) Any and all design rights that may be available to Grantor now or hereafter existing,
created, acquired or held; 
 (d) All patents, patent applications and like protections including, without limitation, improvements,
divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set
forth on Exhibit B attached hereto (collectively, the “Patents”); 
 (e) Any trademark and servicemark rights,
whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth
on Exhibit C attached hereto (collectively, the “Trademarks”); 
 (f) All mask works or similar rights available for
the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”); 

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but
not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above; 

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising
from such use to the extent permitted by such license or rights; 
 (i) All amendments, extensions, renewals and extensions of any of the
Copyrights, Trademarks, Patents, or Mask Works; and 
 (j) All proceeds and products of the foregoing, including without limitation all
payments under insurance or any indemnity or warranty payable in respect of any of the foregoing. 
 Grantor hereby represents and warrants
that the Copyrights set forth on Exhibit A, the Patents set forth on Exhibit B, the Trademarks set forth on Exhibit C and the Mask Works set forth on Exhibit D include, among others, all registered Copyrights, Patents and Trademarks of Grantor on
the date hereof. 
 This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the ratable
benefit of the Lenders under the Loan Agreement, and shall become effective upon the date hereof. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan
Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan
Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers
or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person,
including Collateral Agent, of any or all other rights, powers or remedies. 
 [Signature page follows.] 

  
 2 

 IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be
duly executed by its officers thereunto duly authorized as of the first date written above. 
  

					
		  	GRANTOR:
		
	Address of Grantor:	  	LOMBARD MEDICAL TECHNOLOGIES INC.

					
			
	 15420 Laguna Canyon Road, Suite 260

Irvine, CA 92618
 Attn: Kurt Lemvigh, CEO
	  	By:	  	 /s/ Kurt Lemvigh

		  	Title:	  	CEO

					
		
		  	GRANTOR:
		
		  	ALTURA MEDICAL, INC.

					
			
	 Address of Grantor:
 923 Hamilton Ave.

Menlo Park, CA 94025
 Attn: Kurt Lemvigh, CEO
	  	By:	  	 /s/ Kurt Lemvigh

		  	Title:	  	CEO

					
		
		  	 OXFORD FINANCE LLC, AS COLLATERAL

AGENT AND AS A LENDER

					
	 Address of Lender:
  

133 North Fairfax Street
 Alexandria, Virginia 22314

Attn: Legal Department
	  	By:	  	 /s/ Colette H. Hastings

		  	Title:	  	Senior Vice President

  

 EXHIBIT A 

Copyrights 
 None. 

  

 EXHIBIT B 

Patents 
 [See attached] 

  

 EXHIBIT C 

Trademarks 
 [See attached] 

  

 EXHIBIT D 

Mask Works 
 None.EX-10.8

 Exhibit 10.8 

October 13, 2017 
 LOMBARD MEDICAL
TECHNOLOGIES INC. 
 15420 Laguna Canyon Road, Suite 260 

Irvine, CA 92618 
 ALTURA MEDICAL, INC. 

923 Hamilton Ave. 
 Menlo Park, CA 94025 

Attn: Kurt Lemvigh, CEO 
 Re: Success Fee  

Dear Kurt: 
 This is the “Success Fee
Letter” referred to in that certain Loan and Security Agreement (as the amended, modified, supplemented or restated from time to time, the “Loan Agreement”), dated as of April 24, 2015, by and among OXFORD FINANCE LLC, a
Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent, the lenders listed on Schedule 1.1 thereof or otherwise a party hereto from time to
time including Oxford in its capacity as a lender, and Lombard Medical Technologies Inc., a Delaware corporation with an office located at 15420 Laguna Canyon Road, Suite 260, Irvine CA 92618 (“Lombard Medical”) and ALTURA MEDICAL,
INC., a Delaware corporation with offices located at 923 Hamilton Ave., Menlo Park, CA 94025 (“Altura” and together with Lombard Medical, individually and collectively, jointly and severally, “Borrower”).
Capitalized terms used herein without definition shall have the respective meanings assigned to such terms in the Loan Agreement. 

In addition to any fees, transaction costs, good faith deposits or other amounts payable by Borrower (or any of its affiliates) to
Oxford under the terms of the Loan Agreement or any other Loan Document, Borrower hereby agrees to pay to Oxford a success fee (the “Success Fee”) in the amount of Three Hundred Thousand Dollars ($300,000.00), which shall be
in addition to any other fees or amounts due under any Loan Document, upon the earliest of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, (iii) the prepayment of a Term Loan pursuant to Section 2.2(c) or
(d) of the Loan Agreement, or (iv) the occurrence of a Liquidity Event. 
 The Success Fee will be paid in immediately available
funds and shall not be subject to reduction by way of setoff or counterclaim. All or any portion of the fees received by Oxford hereunder may be allocated, in the sole discretion of Oxford, to any affiliate of Oxford or any other lender in
connection with the syndication of Term Loans. 
 As used herein, “Liquidity Event” shall mean any of the following:
(a) a sale or other disposition by Borrower or any Guarantor of all or substantially all of its assets; (b) a merger or consolidation of Borrower or any Guarantor into or with another person or entity, where the holders of Borrower’s
or such Guarantor’s, as applicable, outstanding voting equity securities as of immediately prior to such merger or consolidation hold less than a majority of the issued and outstanding voting equity securities of the successor or surviving
person or entity as of immediately following the consummation of such merger or consolidation; or (c) any sale, in a single transaction or series of related transactions, by the holders of Borrower’s or any Guarantor’s outstanding
voting equity securities, to one or more buyers, of such securities, where such holders do not, as of immediately following the consummation of such transaction(s), continue to hold at least a majority of Borrower’s or such Guarantor’s
issued and outstanding voting equity securities. 

 This Success Fee Letter, together with the Loan Documents, constitute the entire agreement of the
parties with respect to the subject matter hereof and thereof and supersede any and all previous discussions, communications, understandings or proposals, written or oral, relating in any way to the Term Loans or the subject matter hereof or
thereof. This Success Fee Letter shall govern in the event of any inconsistency with the Loan Documents. 
 Borrower agrees that this
Success Fee Letter is confidential and Borrower agrees that neither this Success Fee Letter nor its contents will be disclosed publicly or privately except: (a) to those individuals who are Borrower’s or any of its Subsidiaries’
officers, employees, directors, stockholders, affiliates, attorneys, accountants, agents or advisors who have a need to know as a result of being involved in the proposed transaction contemplated by the Loan Documents and then only on the condition
that such matters and the contents hereof may not be further disclosed and that such persons are under a binding obligation to keep the contents hereof confidential; (b) in any legal, judicial or administrative proceeding pursuant to a legally
binding request for the disclosure hereof; or (c) in any filings of Borrower with the Securities and Exchange Commission to the extent that this Success Fee Letter or any of its contents are required to be included in such filings under
applicable rules and regulations of the Securities and Exchange Commission. Notwithstanding anything herein to the contrary, to the extent that any disclosure hereof requires to be made pursuant to clause (b) or clause (c) above, Borrower
shall make its good faith and commercially reasonable efforts to (i) notify Oxford at least five (5) days in advance of making such disclosure and (ii) make the least disclosure required under the circumstances. 

It is understood that this Success Fee Letter shall not constitute or give rise to any obligation to provide or arrange any
financing.     
 This Success Fee Letter (i) may be executed in multiple counterparts, each of which shall be
deemed an original and all of which counterparts shall constitute one and the same document, (ii) may be delivered by facsimile or electronic (including “PDF”) transmission and such delivery shall be equally effective as delivery of a
manually executed counterpart hereof, (iii) may not be amended, modified or waived except by an agreement in writing signed by each of the parties hereto, (iv) may not be assigned by Borrower without the prior written consent of Oxford
(and any purported assignment without such consent shall be null and void), and (v) is subject to the governing law, submission to jurisdiction, forum and other provisions of Section 11 of the Loan Agreement.     

[Signature Page follows] 

  
 2 

			
	Very truly yours,
	
	OXFORD FINANCE LLC
		
	By:	 	/s/ Colette H. Hastings
	Name:	 	Colette H. Hastings
	Title:	 	Senior Vice President
	
	ACCEPTED and AGREED:
	
	BORROWER:
	
	LOMBARD MEDICAL TECHNOLOGIES INC.
		
	By	 	 /s/ Kurt Lemvigh

	Name:	 	Kurt Lemvigh
	Title:	 	CEO
	
	BORROWER:
	
	ALTURA MEDICAL, INC.
		
	By	 	 /s/ Kurt Lemvigh

	Name:	 	Kurt Lemvigh
	Title:	 	CEO

  
 [Signature page to
Success Fee Letter]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]